For research use only. Not for therapeutic Use.
SB-215505（Cat No.:I009311） is a potent and subtype-selective antagonist of the 5-HT2B receptor. It exhibits high affinity with pKi values of 8.3, 6.77, and 7.66 for the 5-HT2B, 5-HT2A, and 5-HT2C receptor subtypes, respectively. In preclinical studies involving rats, SB-215505 has been shown to enhance wakefulness and locomotor activity.
| Catalog Number | I009311 |
| CAS Number | 162100-15-4 |
| Synonyms | SB215505; SB 215505; SB-215505.;6-chloro-5-methyl-N-quinolin-5-yl-2,3-dihydroindole-1-carboxamide |
| Molecular Formula | C19H16ClN3O |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| InChI | InChI=1S/C19H16ClN3O/c1-12-10-13-7-9-23(18(13)11-15(12)20)19(24)22-17-6-2-5-16-14(17)4-3-8-21-16/h2-6,8,10-11H,7,9H2,1H3,(H,22,24) |
| InChIKey | HOVMHIRTZYQSKM-UHFFFAOYSA-N |
| SMILES | O=C(N1CCC2=C1C=C(Cl)C(C)=C2)NC3=C4C=CC=NC4=CC=C3 |
| Reference | </br>1: Kantor S, Jakus R, Balogh B, Benko A, Bagdy G. Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505. Br J Pharmacol. 2004 Aug;142(8):1332-42. Epub 2004 Jul 20. PubMed PMID: 15265808; PubMed Central PMCID: PMC1575194. |
